The Pharmacodynamics of the p53-Mdm2 Targeting Drug Nutlin: The Role of Gene-Switching Noise
暂无分享,去创建一个
Alberto Gandolfi | Krzysztof Puszynski | Alberto d'Onofrio | A. d’Onofrio | A. Gandolfi | K. Puszyński
[1] Roberto Barbuti,et al. Tumour suppression by immune system through stochastic oscillations. , 2010, Journal of theoretical biology.
[2] Martin Schuler,et al. Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and Apoptosis , 2004, Science.
[3] Roberto Natalini,et al. A spatial physiological model for p53 intracellular dynamics. , 2013, Journal of theoretical biology.
[4] Jack A. Tuszynski,et al. Stochastic and Deterministic Models of Cellular p53 Regulation , 2013, Front. Oncol..
[5] A. Fersht,et al. Cooperative binding of tetrameric p53 to DNA. , 2004, Journal of molecular biology.
[6] A. Levine,et al. Surfing the p53 network , 2000, Nature.
[7] Alberto d’Onofrio,et al. Bounded Noises in Physics, Biology, and Engineering , 2013 .
[8] Yan Zhao,et al. Abstract 4529: Cellular pharmacokinetic and activity studies with the MDM2-p53 inhibitor Nutlin-3 , 2010 .
[9] T. Mak,et al. Regulation of PTEN transcription by p53. , 2001, Molecular cell.
[10] Fan Zhang,et al. Whole-Body Physiologically Based Pharmacokinetic Model for Nutlin-3a in Mice after Intravenous and Oral Administration , 2011, Drug Metabolism and Disposition.
[11] Antonio Di Cristofano,et al. Class reunion: PTEN joins the nuclear crew , 2005, Oncogene.
[12] J. Beck,et al. Anticancer effects of the p53 activator nutlin-3 in Ewing's sarcoma cells. , 2011, European journal of cancer.
[13] G. Wahl,et al. p53 regulation by post-translational modification and nuclear retention in response to diverse stresses , 1999, Oncogene.
[14] Sachiko Iseki,et al. Inability of p53-reactivating compounds Nutlin-3 and RITA to overcome p53 resistance in tumor cells deficient in p53Ser46 phosphorylation. , 2012, Biochemical and biophysical research communications.
[15] Duccio Fanelli,et al. A dynamical model of apoptosis and its role in tumor progression , 2012 .
[16] P. Meltzer,et al. Amplification of a gene encoding a p53-associated protein in human sarcomas , 1992, Nature.
[17] Andrea Ciliberto,et al. Steady States and Oscillations in the p53/Mdm2 Network , 2005, Cell cycle.
[18] Samuel Bottani,et al. Analysis of a minimal model for p53 oscillations. , 2007, Journal of theoretical biology.
[19] M. Chaplain,et al. Spatial stochastic modelling of the Hes1 gene regulatory network: intrinsic noise can explain heterogeneity in embryonic stem cell differentiation , 2013, Journal of The Royal Society Interface.
[20] Seth Michelson,et al. Systems Biology in Drug Discovery and Development: Young/Systems Bio in Drug Discovery , 2011 .
[21] J. Li,et al. MiR‐125b inhibits cell biological progression of Ewing's sarcoma by suppressing the PI3K/Akt signalling pathway , 2014, Cell proliferation.
[22] Gabriel Pons,et al. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. , 2006, Blood.
[23] T. Elston,et al. Stochasticity in gene expression: from theories to phenotypes , 2005, Nature Reviews Genetics.
[24] Masaki Mori,et al. MicroRNA miR-125b is a prognostic marker in human colorectal cancer. , 2011, International journal of oncology.
[25] A. Monteiro,et al. Phosphatases in the cellular response to DNA damage , 2010, Cell Communication and Signaling.
[26] J. Levine,et al. Surfing the p53 network , 2000, Nature.
[27] L. Mayo,et al. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[28] L. Vassilev,et al. In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.
[29] R. Sachidanandam,et al. A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis , 2013, Cell Death and Differentiation.
[30] N. Monk. Oscillatory Expression of Hes1, p53, and NF-κB Driven by Transcriptional Time Delays , 2003, Current Biology.
[31] G. Wahl,et al. Accelerated MDM2 auto‐degradation induced by DNA‐damage kinases is required for p53 activation , 2004, The EMBO journal.
[32] D. Tranchina,et al. Stochastic mRNA Synthesis in Mammalian Cells , 2006, PLoS biology.
[33] K. Sneppen,et al. Oscillations and temporal signalling in cells , 2007, Physical biology.
[34] G. Wahl,et al. Targeting Mdm2 and Mdmx in Cancer Therapy: Better Living through Medicinal Chemistry? , 2009, Molecular Cancer Research.
[35] Roman Jaksik,et al. Regulation of p53 by siRNA in radiation treated cells: Simulation studies , 2012, Int. J. Appl. Math. Comput. Sci..
[36] C. Maki,et al. Persistent p21 Expression after Nutlin-3a Removal Is Associated with Senescence-like Arrest in 4N Cells , 2010, The Journal of Biological Chemistry.
[37] A. Gudkov,et al. Cellular quiescence caused by the Mdm2 inhibitor Nutlin-3A , 2009, Cell cycle.
[38] Fangyi Zhu,et al. Targeting the p53 pathway in retinoblastoma with subconjunctival Nutlin-3a. , 2011, Cancer research.
[39] Wei Wang,et al. Two-phase dynamics of p53 in the DNA damage response , 2011, Proceedings of the National Academy of Sciences.
[40] Kyoohyoung Rho,et al. A theoretical model for p53 dynamics: Identifying optimal therapeutic strategy for its activation and stabilization , 2009, Cell cycle.
[41] M. Groudine,et al. Enhancers increase the probability but not the level of gene expression. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[42] Zigang Dong,et al. Post-translational modification of p53 in tumorigenesis , 2004, Nature Reviews Cancer.
[43] Wei Wang,et al. Coordination between Cell Cycle Progression and Cell Fate Decision by the p53 and E2F1 Pathways in Response to DNA Damage* , 2010, The Journal of Biological Chemistry.
[44] Binh Vu,et al. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models. , 2013, Cancer research.
[45] Xuejun Jiang,et al. MdmX Protein Is Essential for Mdm2 Protein-mediated p53 Polyubiquitination , 2011, The Journal of Biological Chemistry.
[46] M. Oren,et al. Mdm2 promotes the rapid degradation of p53 , 1997, Nature.
[47] Baoying Huang,et al. Pharmacologic p53 Activation Blocks Cell Cycle Progression but Fails to Induce Senescence in Epithelial Cancer Cells , 2009, Molecular Cancer Research.
[48] Jiandong Chen,et al. MDMX regulation of p53 response to ribosomal stress , 2006, The EMBO journal.
[49] Dajun Yang,et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition , 2008, Proceedings of the National Academy of Sciences.
[50] Pier Paolo Di Fiore,et al. The Tumor Suppressor p53 Regulates Polarity of Self-Renewing Divisions in Mammary Stem Cells , 2009, Cell.
[51] U Alon,et al. Generation of oscillations by the p53-Mdm2 feedback loop: a theoretical and experimental study. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[52] Huey-Jen Lin,et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. , 2010, Cancer cell.
[53] Michael A. Dyer,et al. Inactivation of the p53 pathway in retinoblastoma , 2006, Nature.
[54] L. Jeffrey Medeiros,et al. Inhibition of p53-Murine Double Minute 2 Interaction by Nutlin-3A Stabilizes p53 and Induces Cell Cycle Arrest and Apoptosis in Hodgkin Lymphoma , 2007, Clinical Cancer Research.
[55] Baoli Hu,et al. MDMX Overexpression Prevents p53 Activation by the MDM2 Inhibitor Nutlin* , 2006, Journal of Biological Chemistry.
[56] Laurence Choulier,et al. Activation of p53 pathway by Nutlin-3a inhibits the expression of the therapeutic target α5 integrin in colon cancer cells. , 2013, Cancer letters.
[57] Jing Zhang,et al. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. , 2013, Journal of medicinal chemistry.
[58] B. Kholodenko. Cell-signalling dynamics in time and space , 2006, Nature Reviews Molecular Cell Biology.
[59] H. Lodish,et al. MicroRNA-125b is a novel negative regulator of p53. , 2009, Genes & development.
[60] Marc Sturrock,et al. Spatio-temporal modelling of the Hes1 and p53-Mdm2 intracellular signalling pathways. , 2011, Journal of theoretical biology.
[61] Y. E. Chen,et al. Vemurafenib Synergizes with Nutlin-3 to Deplete Survivin and Suppresses Melanoma Viability and Tumor Growth , 2013, Clinical Cancer Research.
[62] Shiwei Yan,et al. A unified model for studying DNA damage-induced p53–Mdm2 interaction , 2006 .
[63] O. Myklebost,et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[64] Baoying Huang,et al. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation , 2008, Cell cycle.
[65] D. Gillespie. Exact Stochastic Simulation of Coupled Chemical Reactions , 1977 .
[66] Pradeep Kumar Shreenivasaiah,et al. microRNA Regulation of Networks of Normal and Cancer Cells , 2010 .
[67] Jun S. Song,et al. Negative regulation of tumor suppressor p53 by microRNA miR-504. , 2010, Molecular cell.
[68] Jean-Christophe Marine,et al. Mdmx as an essential regulator of p53 activity. , 2005, Biochemical and biophysical research communications.
[69] Sandeep Krishna,et al. Stress-specific response of the p53-Mdm2 feedback loop , 2010, BMC Systems Biology.
[70] Jun Li,et al. A Two-Step Mechanism for Cell Fate Decision by Coordination of Nuclear and Mitochondrial p53 Activities , 2012, PloS one.
[71] Patrick W. Lee,et al. Biogenesis of p53 Involves Cotranslational Dimerization of Monomers and Posttranslational Dimerization of Dimers , 2002, The Journal of Biological Chemistry.
[72] J. Acebes,et al. Activation of p53 by Nutlin-3a Induces Apoptosis and Cellular Senescence in Human Glioblastoma Multiforme , 2011, PloS one.
[73] T. Kepler,et al. Stochasticity in transcriptional regulation: origins, consequences, and mathematical representations. , 2001, Biophysical journal.
[74] E. Appella,et al. Wip1 phosphatase modulates ATM-dependent signaling pathways. , 2006, Molecular cell.
[75] D. Meek,et al. Multisite phosphorylation and the integration of stress signals at p53. , 1998, Cellular signalling.
[76] Tak W. Mak,et al. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis , 2006, Nature Reviews Cancer.
[77] Alan J. Terry,et al. Influence of the Nuclear Membrane, Active Transport, and Cell Shape on the Hes1 and p53–Mdm2 Pathways: Insights from Spatio-temporal Modelling , 2012, Bulletin of mathematical biology.
[78] Tomasz Lipniacki,et al. Oscillations and bistability in the stochastic model of p53 regulation. , 2008, Journal of theoretical biology.
[79] Giancarlo Mauri,et al. The Interplay of Intrinsic and Extrinsic Bounded Noises in Biomolecular Networks , 2012, PloS one.
[80] Jindrich Cinatl,et al. Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3. , 2009, Cancer research.
[81] Hong Yang,et al. Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. , 2005, Cancer research.
[82] Alberto Gandolfi,et al. Resistance to antitumor chemotherapy due to bounded-noise-induced transitions. , 2010, Physical review. E, Statistical, nonlinear, and soft matter physics.
[83] E. Wang. MicroRNA Systems Biology , 2007, 0712.3569.
[84] Marek Kimmel,et al. Single TNFα trimers mediating NF-κB activation: stochastic robustness of NF-κB signaling , 2007, BMC Bioinformatics.
[85] John Jeremy Rice,et al. A plausible model for the digital response of p53 to DNA damage. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[86] T Maimets,et al. Activation of p53 by nutlin leads to rapid differentiation of human embryonic stem cells , 2008, Oncogene.
[87] Anang A. Shelat,et al. First Small Molecule Inhibitor of MDMX Identification and Characterization of the Cell Biology : , 2010 .
[88] Paul Brazhnik,et al. HAUSP-regulated switch from auto- to p53 ubiquitination by Mdm2 (in silico discovery). , 2007, Mathematical biosciences.
[89] H. Hermeking,et al. MicroRNAs in the p53 network: micromanagement of tumour suppression , 2012, Nature Reviews Cancer.
[90] M. Ko,et al. A stochastic model for gene induction. , 1991, Journal of theoretical biology.
[91] Daniel J. Freeman,et al. PTEN Regulates Mdm2 Expression through the P1 Promoter* , 2004, Journal of Biological Chemistry.
[92] F S Fay,et al. Visualization of single RNA transcripts in situ. , 1998, Science.
[93] E. Berg. Systems biology in drug discovery and development. , 2014, Drug discovery today.
[94] Roser Mir,et al. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild‐type ovarian cancer cells , 2013, International journal of cancer.